Warner Chilcott Reports Operating Results for the Quarter Ended Septembe... (the decline in prescription demand and n...)

Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007

Date:11/9/2007

the decline in prescription demand and net sales will accelerate in the fourth quarter of 2007 as generic versions of ESTROSTEP were introduced in late October 2007. Following the launch of a generic ESTROSTEP product by Barr Laboratories, Inc., we partnered with Watson Pharma, Inc. to launch Tilia(TM), an authorized generic version of ESTROSTEP. OVCON net sales declined $16.1 million, or 75.6%, for the quarter ended September 30, 2007 compared with the prior year quarter. The decline in OVCON revenue was primarily due to the introduction of generic versions of OVCON 35 beginning in late October 2006, which led to an 88.3% decline in filled prescriptions for OVCON 35 for the quarter ended September 30, 2007 compared to the prior year quarter.

Sales of our dermatology products increased $14.1 million, or 17.7%, in the quarter ended September 30, 2007 compared to the prior year quarter, primarily due to a $13.4 million increase in TACLONEX sales. The increase in filled prescriptions for TACLONEX of 49.1% compared to the prior year quarter, was the primary driver of the increase in net sales. Net sales of DORYX increased $4.6 million, or 18.7%, in the quarter ended September 30, 2007 compared with the prior year quarter due to increased demand and higher average selling prices. DORYX prescriptions had been declining through the first half of 2007. In January 2007, we took steps to increase our Dermatology sales force's promotional efforts with DORYX and those changes resulted in filled prescriptions of DORYX increasing 2.2% in the quarter ended September 30, 2007 compared to the prior year quarter. Sales of DOVONEX decreased $3.9 million, or 10.8%, in the quarter ended September 30, 2007 compared with the prior year quarter due to an 18.3% decline in filled prescriptions. The decline in filled prescriptions was partially offset by higher selling prices in the quarter compared with the prior year quarter. We believe the decline in filled prescriptions of DOVONEX
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Related medicine news :

1. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
2. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance

Post Your Comments:

Warner Chilcott Reports Operating Results for the Quarter Ended Septembe...(the decline in prescription demand and n...),Health